Camurus Ab News - 0RD1

Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Trea...

Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Treatment of Opioid...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From the US market PR...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From the US market PR...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Dependence PR Newswire LUND...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Dependence The Australian...

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™ PR Newswire LUND, Sweden, July 23, 2019 FDA ordered...

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™ FDA ordered to reconsider, with deliberate speed...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan PR...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan FluidCrystal®...

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly PR Newswire LUND, Sweden, June 20, 2019...

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly PR Newswire LUND, Sweden, June 20, 2019...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With Buvidal® PR...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfaction With...

Camurus Interim Report January-March 2019

Camurus Interim Report January-March 2019 PR Newswire STOCKHOLM, May 9, 2019 STOCKHOLM, May 9, 2019 /PRNewswire/ -- "Initial sales of Buvidal®...

Camurus Interim Report January-March 2019

Camurus Interim Report January-March 2019 PR Newswire STOCKHOLM, May 9, 2019 STOCKHOLM, May 9, 2019 /PRNewswire/ -- "Initial sales of Buvidal®...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Camurus Ab (0RD1)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

0RD1 News

Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Trea...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Interim Report January-March 2019

Camurus Interim Report January-March 2019

0RD1 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Camurus Ab (0RD1) News

Camurus Ab (0RD1)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

0RD1 News

Camurus Announces New Study Results Showing Superior Patient Reported Outcomes With Buvidal® Versus Standard of Care in Trea...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus Announces That FDA Grants Braeburn's Citizen Petition, Eliminating the Risk of Further Blocking of Brixadi™ From th...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus: Australian Minister for Health Announced PBS Listing of Buvidal® Weekly and Monthly for Treatment of Opioid Depende...

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Camurus Announces Positive Outcome of U.S. Court Proceeding About Final Approval of Brixadi™

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Ziluco...

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Announces Publication of Phase 3 Study Results Showing Long-term Safety, Efficacy and High Rates of Patient Satisfact...

Camurus Interim Report January-March 2019

Camurus Interim Report January-March 2019

0RD1 Discussion

Your Recent History